Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jason L Vittitow"'
Autor:
Ahmad M. Fahmy, Jennifer S. Harthan, David G. Evans, Jack V. Greiner, Joseph Tauber, John D. Sheppard, Sonja Krösser, Jason L. Vittitow
Publikováno v:
Frontiers in Ophthalmology, Vol 4 (2024)
BackgroundDry eye disease (DED) is commonly caused by excessive tear film evaporation due to Meibomian gland dysfunction (MGD). There is a need for DED treatment options that address tear evaporation and benefit patients across a broad range of demog
Externí odkaz:
https://doaj.org/article/d4572072e7f04837aa628162d8099232
Autor:
Peter Couroux, Alexandre Brkovic, Jason L. Vittitow, Robert J. Israel, Chinna Pamidi, Jignesh Patel, Maxime Barakat
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2159-2171 (2022)
Abstract Ribavirin is an inosine monophosphate dehydrogenase inhibitor. Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses. However, current treatment is long (12–18 h per day, 3–
Externí odkaz:
https://doaj.org/article/64286b44217a485795376ac88fad47fa
Publikováno v:
American Journal of Ophthalmology. 252:265-274
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4068f3a1f729c37375432b85bcddb90
https://doi.org/10.1016/j.ajo.2023.03.008
https://doi.org/10.1016/j.ajo.2023.03.008
Publikováno v:
Ophthalmology.
To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop in patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD).Eight-week, phase 3, multicenter, randomized, double-masked, saline-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a551ba910fce5db8f596c11dc519e94
https://pubmed.ncbi.nlm.nih.gov/36574848
https://pubmed.ncbi.nlm.nih.gov/36574848
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Raymond Fong,1 Megan E Cavet,2 Heleen H DeCory,2 Jason L Vittitow31Manhattan Eye, Ear and Throat Hospital and Lenox Hill Hospital, New York, NY, USA; 2Medical Affairs, Bausch + Lomb, Rochester, NY, USA; 3Clinical Affairs, Bausch + Lomb, Bridgewater,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01661bf79ae29f09a86f5fb813125e37
https://doi.org/10.2147/opth.s210597
https://doi.org/10.2147/opth.s210597
Autor:
Jon Williams, Jason L Vittitow
Publikováno v:
Journal of cataract and refractive surgery. 46(8)
Purpose To compare loteprednol etabonate (LE) gel 0.5% with prednisolone acetate suspension (PA) 1% for the treatment of inflammation after cataract surgery in children. Setting Eleven sites in the United States. Design Randomized, double-masked, par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8894253a25aef08c062e3fb9937da54e
https://pubmed.ncbi.nlm.nih.gov/32352250
https://pubmed.ncbi.nlm.nih.gov/32352250
Publikováno v:
Clinical & Experimental Optometry
BACKGROUND The aim of this study was to provide an integrated analysis of safety and efficacy data for brimonidine tartrate ophthalmic solution 0.025 per cent (low-dose; Bausch & Lomb Incorporated), a topical vasoconstrictor for relief of ocular redn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d13f3ef73239c521e7a45520255aaaac
http://europepmc.org/articles/PMC6587872
http://europepmc.org/articles/PMC6587872
Publikováno v:
Journal of Cataract and Refractive Surgery. 44:1220-1229
To assess the safety and efficacy of a 0.38% submicron formulation of loteprednol etabonate (LE) gel for the treatment of postoperative inflammation and pain after cataract surgery.Forty-five United States ophthalmology practices.Double-masked vehicl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c64a1c72bdde5be72d64776ed9f8a20
https://doi.org/10.1016/j.jcrs.2018.06.056
https://doi.org/10.1016/j.jcrs.2018.06.056
Publikováno v:
Journal of glaucoma, vol 27, iss 1
J Glaucoma
J Glaucoma
PURPOSE:To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). PATIENTS AND METHODS:Pooled analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191b13cafc3c8e47a3a5bcf792376bce
https://doi.org/10.1097/ijg.0000000000000831
https://doi.org/10.1097/ijg.0000000000000831
Autor:
John R. Slight, Baldo Scassellati Sforzolini, Jason L Vittitow, Robert N. Weinreb, John H.K. Liu
Publikováno v:
American Journal of Ophthalmology. 169:249-257
PurposeTo compare the diurnal and nocturnal effects of latanoprostene bunod 0.024% solution with timolol maleate 0.5% solution on intraocular pressure (IOP) and ocular perfusion pressure.DesignProspective, open-label randomized crossover trial.Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0c29498f9dd237c48fe8de50ca5b0ee